Literature DB >> 2084072

Phase II trial of echinomycin in advanced soft tissue sarcomas. A Southwest Oncology Group study.

S A Taylor1, B Metch, S P Balcerzak, K H Hanson.   

Abstract

Thirty-four patients with advanced soft tissue sarcomas were entered in a phase II trial of echinomycin. Patients received 1.2 mg/m2 intravenously (i.v.) weekly times four followed by a two week rest period. There were no objective responses. Dose limiting toxicity was gastrointestinal. Echinomycin given on this weekly schedule is inactive in treating previously treated patients with advanced soft tissue sarcomas.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2084072     DOI： 10.1007/BF00198595

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


  3 in total

1.  Phase I study of echinomycin.

Authors:  R Pazdur; C D Haas; L H Baker; C G Leichman; D Decker
Journal:  Cancer Treat Rep       Date:  1987-12

2.  Intermolecular cross-linking of DNA through bifunctional intercalation of an antitumor antibiotic, luzopeptin A (BBM-928A).

Authors:  C H Huang; C K Mirabelli; S Mong; S T Crooke
Journal:  Cancer Res       Date:  1983-06       Impact factor: 12.701

3.  Phase I study of echinomycin administered on an intermittent bolus schedule.

Authors:  J H Harvey; M McFadden; W G Andrews; P J Byrne; J D Ahlgren; P V Woolley
Journal:  Cancer Treat Rep       Date:  1985-12
  3 in total
  3 in total

1.  Liposomal formulation of HIF-1α inhibitor echinomycin eliminates established metastases of triple-negative breast cancer.

Authors:  Christopher M Bailey; Yan Liu; Gong Peng; Huixia Zhang; Miao He; Duxin Sun; Pan Zheng; Yang Liu; Yin Wang
Journal:  Nanomedicine       Date:  2020-07-30       Impact factor: 5.307

2.  Characterization of Streptomyces sp. LS462 with high productivity of echinomycin, a potent antituberculosis and synergistic antifungal antibiotic.

Authors:  Caixia Chen; Xiangyin Chen; Biao Ren; Hui Guo; Wael M Abdel-Mageed; Xueting Liu; Fuhang Song; Lixin Zhang
Journal:  J Ind Microbiol Biotechnol       Date:  2021-12-23       Impact factor: 4.258

3.  Quinomycin A targets Notch signaling pathway in pancreatic cancer stem cells.

Authors:  Sivapriya Ponnurangam; Prasad R Dandawate; Animesh Dhar; Ossama W Tawfik; Rajashri R Parab; Prabhu Dutt Mishra; Prafull Ranadive; Rajiv Sharma; Girish Mahajan; Shahid Umar; Scott J Weir; Aravind Sugumar; Roy A Jensen; Subhash B Padhye; Arun Balakrishnan; Shrikant Anant; Dharmalingam Subramaniam
Journal:  Oncotarget       Date:  2016-01-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.